NYSEARCA:CANF - NYSE Arca - US13471N3008 - ADR - Currency: USD
1.1
+0.01 (+0.92%)
The current stock price of CANF is 1.1 USD. In the past month the price decreased by -17.29%. In the past year, price decreased by -47.37%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.31 | 332.73B | ||
AMGN | AMGEN INC | 13.29 | 148.31B | ||
GILD | GILEAD SCIENCES INC | 12.78 | 123.13B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.78B | ||
REGN | REGENERON PHARMACEUTICALS | 12.66 | 60.56B | ||
ARGX | ARGENX SE - ADR | 327.86 | 38.04B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.97B | ||
ONC | BEIGENE LTD-ADR | N/A | 25.03B | ||
BNTX | BIONTECH SE-ADR | N/A | 22.31B | ||
NTRA | NATERA INC | N/A | 21.77B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.04B | ||
BIIB | BIOGEN INC | 7.41 | 17.17B |
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
CAN FITE BIOPHARMA LTD-ADR
26 Ben Gurion Street
Ramat Gan 4951778 IL
CEO: Pnina Fishman
Employees: 5
Phone: 97239241114
The current stock price of CANF is 1.1 USD. The price increased by 0.92% in the last trading session.
The exchange symbol of CAN FITE BIOPHARMA LTD-ADR is CANF and it is listed on the NYSE Arca exchange.
CANF stock is listed on the NYSE Arca exchange.
8 analysts have analysed CANF and the average price target is 7.96 USD. This implies a price increase of 623.27% is expected in the next year compared to the current price of 1.1. Check the CAN FITE BIOPHARMA LTD-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CAN FITE BIOPHARMA LTD-ADR (CANF) has a market capitalization of 14.14M USD. This makes CANF a Nano Cap stock.
CAN FITE BIOPHARMA LTD-ADR (CANF) currently has 5 employees.
CAN FITE BIOPHARMA LTD-ADR (CANF) has a resistance level at 1.15. Check the full technical report for a detailed analysis of CANF support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CANF does not pay a dividend.
CAN FITE BIOPHARMA LTD-ADR (CANF) will report earnings on 2025-08-28.
CAN FITE BIOPHARMA LTD-ADR (CANF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).
The outstanding short interest for CAN FITE BIOPHARMA LTD-ADR (CANF) is 10.28% of its float. Check the ownership tab for more information on the CANF short interest.
ChartMill assigns a fundamental rating of 3 / 10 to CANF. While CANF seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months CANF reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS increased by 40% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -86.4% | ||
ROE | -144.96% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to CANF. The Buy consensus is the average rating of analysts ratings from 8 analysts.